Not to be used in patients w/ asthma. Discontinue treatment if paradoxical bronchospasm occurs. Not for treatment of acute episodes of bronchospasm. Re-evaluate patient & treatment regimen in the event of COPD deterioration during treatment. Patients w/ severe CV disease; urinary retention or narrow-angle glaucoma; convulsive disorders or thyrotoxicosis & in those who are unusually responsive to β2-adrenergic agonists. Concomitant use w/ other drugs that have potential to cause hypokalaemia. Closely monitor plasma glucose in diabetic patients upon initiation of treatment. Contains lactose; not to be taken by patients w/ rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption. Severe hepatic impairment. Pregnancy & lactation. Childn <18 yr.
R03AL03 - vilanterol and umeclidinium bromide ; Belongs to the class of combination of adrenergics with anticholinergics, that may also include a corticosteroid. Used in the treatment of obstructive airway diseases.
Sign Out
